Sernova Corp. (TSE:SVA – Free Report) – Equities researchers at Ventum Cap Mkts issued their FY2025 earnings per share (EPS) estimates for shares of Sernova in a report issued on Tuesday, September 17th. Ventum Cap Mkts analyst S. Quenneville expects that the company will earn ($0.10) per share for the year. Ventum Cap Mkts currently has a “Strong-Buy” rating on the stock. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share.
Sernova (TSE:SVA – Get Free Report) last announced its earnings results on Monday, September 16th. The company reported C($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C($0.03) by C$0.01.
Get Our Latest Stock Report on Sernova
Sernova Price Performance
Shares of TSE SVA opened at C$0.25 on Thursday. Sernova has a twelve month low of C$0.20 and a twelve month high of C$0.83. The company has a current ratio of 0.62, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55. The company has a market capitalization of C$79.48 million, a price-to-earnings ratio of -1.88 and a beta of 1.38. The business has a 50 day simple moving average of C$0.26 and a 200-day simple moving average of C$0.36.
Insider Buying and Selling
In related news, Director Steven Sangha sold 930,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total transaction of C$223,200.00. Insiders purchased a total of 379,600 shares of company stock worth $97,671 in the last three months. 12.98% of the stock is owned by insiders.
Sernova Company Profile
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.
See Also
- Five stocks we like better than Sernova
- How to Invest in the FAANG Stocks
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Upcoming IPO Stock Lockup Period, Explained
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.